Treatment of Menorrhagia with an Antifibrinolytic Agent, Tranexamic Acid (Amca): A Double Blind Investigation

Treatment of menorrhagia with an antifibrinolytic agent tranexamic acid (AMCA) was investigated by double-blind trial and dose-response studies. 36 women aged 15-49 years were included in the study. The decrease in blood loss during AMCA treatment was statistically significant (.05 < p < .1). No difference was seen between the women with and those without fibroids. 17 of the women reported no side effects. 2 women had side effects only with the placebo and 6 did so on both regimens. In 7 women side effects occurred only with the high dosage. The main side effects were diarrhea and abdominal pains.